Trials / Recruiting
RecruitingNCT05808634
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients With Advanced Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 168 (estimated)
- Sponsor
- BioAtla, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Detailed description
This is a multi-center, open-label, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3182 in patients with advanced adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BA3182 | Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM |
Timeline
- Start date
- 2023-07-14
- Primary completion
- 2028-09-15
- Completion
- 2028-09-15
- First posted
- 2023-04-11
- Last updated
- 2025-09-25
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05808634. Inclusion in this directory is not an endorsement.